Effect of canagliflozin in non-diabetic obese patients with albuminuria: A randomized, double-blind, placebo-controlled trial
CONCLUSION: Canagliflozin 100 mg daily was well tolerated but did not significantly reduce UACR in non-diabetic obese patients with microalbuminuria. However, a significant temporary decline in eGFR might reflect a subtle reduction in glomerular hyperfiltration.PMID:37675488 | DOI:10.5414/CN111143 (Source: Clinical Nephrology)
Source: Clinical Nephrology - September 7, 2023 Category: Urology & Nephrology Authors: Primploy Greeviroj Pongpratch Puapatanakul Jeerath Phannajit Kullaya Takkavatakarn Wonngarm Kittanamongkolchai Patchaya Boonchaya-Anant Pisut Katavetin Kearkiat Praditpornsilpa Somchai Eiam-Ong Paweena Susantitaphong Source Type: research
Effect of canagliflozin in non-diabetic obese patients with albuminuria: A randomized, double-blind, placebo-controlled trial
CONCLUSION: Canagliflozin 100 mg daily was well tolerated but did not significantly reduce UACR in non-diabetic obese patients with microalbuminuria. However, a significant temporary decline in eGFR might reflect a subtle reduction in glomerular hyperfiltration.PMID:37675488 | DOI:10.5414/CN111143 (Source: Clinical Nephrology)
Source: Clinical Nephrology - September 7, 2023 Category: Urology & Nephrology Authors: Primploy Greeviroj Pongpratch Puapatanakul Jeerath Phannajit Kullaya Takkavatakarn Wonngarm Kittanamongkolchai Patchaya Boonchaya-Anant Pisut Katavetin Kearkiat Praditpornsilpa Somchai Eiam-Ong Paweena Susantitaphong Source Type: research
Effect of canagliflozin in non-diabetic obese patients with albuminuria: A randomized, double-blind, placebo-controlled trial
CONCLUSION: Canagliflozin 100 mg daily was well tolerated but did not significantly reduce UACR in non-diabetic obese patients with microalbuminuria. However, a significant temporary decline in eGFR might reflect a subtle reduction in glomerular hyperfiltration.PMID:37675488 | DOI:10.5414/CN111143 (Source: Clinical Nephrology)
Source: Clinical Nephrology - September 7, 2023 Category: Urology & Nephrology Authors: Primploy Greeviroj Pongpratch Puapatanakul Jeerath Phannajit Kullaya Takkavatakarn Wonngarm Kittanamongkolchai Patchaya Boonchaya-Anant Pisut Katavetin Kearkiat Praditpornsilpa Somchai Eiam-Ong Paweena Susantitaphong Source Type: research
Effect of canagliflozin in non-diabetic obese patients with albuminuria: A randomized, double-blind, placebo-controlled trial
CONCLUSION: Canagliflozin 100 mg daily was well tolerated but did not significantly reduce UACR in non-diabetic obese patients with microalbuminuria. However, a significant temporary decline in eGFR might reflect a subtle reduction in glomerular hyperfiltration.PMID:37675488 | DOI:10.5414/CN111143 (Source: Clinical Nephrology)
Source: Clinical Nephrology - September 7, 2023 Category: Urology & Nephrology Authors: Primploy Greeviroj Pongpratch Puapatanakul Jeerath Phannajit Kullaya Takkavatakarn Wonngarm Kittanamongkolchai Patchaya Boonchaya-Anant Pisut Katavetin Kearkiat Praditpornsilpa Somchai Eiam-Ong Paweena Susantitaphong Source Type: research
Effect of canagliflozin in non-diabetic obese patients with albuminuria: A randomized, double-blind, placebo-controlled trial
CONCLUSION: Canagliflozin 100 mg daily was well tolerated but did not significantly reduce UACR in non-diabetic obese patients with microalbuminuria. However, a significant temporary decline in eGFR might reflect a subtle reduction in glomerular hyperfiltration.PMID:37675488 | DOI:10.5414/CN111143 (Source: Clinical Nephrology)
Source: Clinical Nephrology - September 7, 2023 Category: Urology & Nephrology Authors: Primploy Greeviroj Pongpratch Puapatanakul Jeerath Phannajit Kullaya Takkavatakarn Wonngarm Kittanamongkolchai Patchaya Boonchaya-Anant Pisut Katavetin Kearkiat Praditpornsilpa Somchai Eiam-Ong Paweena Susantitaphong Source Type: research
Effect of canagliflozin in non-diabetic obese patients with albuminuria: A randomized, double-blind, placebo-controlled trial
CONCLUSION: Canagliflozin 100 mg daily was well tolerated but did not significantly reduce UACR in non-diabetic obese patients with microalbuminuria. However, a significant temporary decline in eGFR might reflect a subtle reduction in glomerular hyperfiltration.PMID:37675488 | DOI:10.5414/CN111143 (Source: Clinical Nephrology)
Source: Clinical Nephrology - September 7, 2023 Category: Urology & Nephrology Authors: Primploy Greeviroj Pongpratch Puapatanakul Jeerath Phannajit Kullaya Takkavatakarn Wonngarm Kittanamongkolchai Patchaya Boonchaya-Anant Pisut Katavetin Kearkiat Praditpornsilpa Somchai Eiam-Ong Paweena Susantitaphong Source Type: research
Proteomic changes induced by longevity-promoting interventions in mice
AbstractUsing mouse models and high-throughput proteomics, we conducted an in-depth analysis of the proteome changes induced in response to seven interventions known to increase mouse lifespan. This included two genetic mutations, a growth hormone receptor knockout (GHRKO mice) and a mutation in thePit-1 locus (Snell dwarf mice), four drug treatments (rapamycin, acarbose, canagliflozin, and 17 α-estradiol), and caloric restriction. Each of the interventions studied induced variable changes in the concentrations of proteins across liver, kidney, and gastrocnemius muscle tissue samples, with the strongest responses in the l...
Source: AGE - August 31, 2023 Category: Geriatrics Source Type: research
Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials
ConclusionIn patients with T2DM, dapagliflozin was associated with an increased risk of RTIs, pollakiuria, and UTIs. Empagliflozin increased the risk of RTIs and pollakiuria. Remogliflozin increased the risk of UTIs. None of the SGLT-2 inhibitors showed a significant difference from the placebo for hypovolemia, renal impairment or failure, fracture, DKA, amputation, and severe hypoglycemia. The findings guide the selection of SGLT-2 inhibitors for patients with T2DM based on the patient’s profiles to maximize safety.Systematic review registrationhttps://www.crd.york.ac.uk/prospero, identifier CRD42022334644. (Source: Fro...
Source: Frontiers in Endocrinology - August 28, 2023 Category: Endocrinology Source Type: research
Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial
CONCLUSIONS: Multiple cardiorenal stress biomarkers are strongly prognostic in people with type 2 diabetes and albuminuria. Canagliflozin modestly reduced the longitudinal trajectory of rise in each biomarker. Change in the biomarker level in addition to the baseline level augments the primary outcome prediction.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT02065791.PMID:37603600 | DOI:10.1161/CIRCULATIONAHA.123.065251 (Source: Circulation)
Source: Circulation - August 21, 2023 Category: Cardiology Authors: James L Januzzi Reza Mohebi Yuxi Liu Naveed Sattar Hiddo J L Heerspink Eshetu Tefera Muthiah Vaduganathan Javed Butler Yshai Yavin Jingwei Li Carol A Pollock Vlado Perkovic Bruce Neal Michael K Hansen Source Type: research
Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial
CONCLUSIONS: Multiple cardiorenal stress biomarkers are strongly prognostic in people with type 2 diabetes and albuminuria. Canagliflozin modestly reduced the longitudinal trajectory of rise in each biomarker. Change in the biomarker level in addition to the baseline level augments the primary outcome prediction.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT02065791.PMID:37603600 | DOI:10.1161/CIRCULATIONAHA.123.065251 (Source: Circulation)
Source: Circulation - August 21, 2023 Category: Cardiology Authors: James L Januzzi Reza Mohebi Yuxi Liu Naveed Sattar Hiddo J L Heerspink Eshetu Tefera Muthiah Vaduganathan Javed Butler Yshai Yavin Jingwei Li Carol A Pollock Vlado Perkovic Bruce Neal Michael K Hansen Source Type: research
Canagliflozin alleviates experimentally induced benign prostate hyperplasia in a rat model: exploring potential mechanisms involving mir-128b/EGFR/EGF and JAK2/STAT3 signaling pathways through in silico and in vivo investigations
Eur J Pharmacol. 2023 Aug 18:175993. doi: 10.1016/j.ejphar.2023.175993. Online ahead of print.ABSTRACTBenign prostatic hyperplasia (BPH) poses a significant health concern amongst elderly males. Canagliflozin (Cana), a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, has a powerful anti-inflammatory influence. Nevertheless, its role in treating BPH has not been clarified. Therefore, the study aimed to investigate the potential ameliorative effect of Cana on experimentally induced BPH in rats and explore the underlying mechanisms compared to the standard finasteride (Fin). The study employed histological analysi...
Source: European Journal of Pharmacology - August 20, 2023 Category: Drugs & Pharmacology Authors: Eman M Elbaz Alshaymaa Darwish Amany M Gad Amina A S Abdel Rahman Maheera H Safwat Source Type: research
Canagliflozin alleviates experimentally induced benign prostate hyperplasia in a rat model: exploring potential mechanisms involving mir-128b/EGFR/EGF and JAK2/STAT3 signaling pathways through in silico and in vivo investigations
Eur J Pharmacol. 2023 Aug 18:175993. doi: 10.1016/j.ejphar.2023.175993. Online ahead of print.ABSTRACTBenign prostatic hyperplasia (BPH) poses a significant health concern amongst elderly males. Canagliflozin (Cana), a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, has a powerful anti-inflammatory influence. Nevertheless, its role in treating BPH has not been clarified. Therefore, the study aimed to investigate the potential ameliorative effect of Cana on experimentally induced BPH in rats and explore the underlying mechanisms compared to the standard finasteride (Fin). The study employed histological analysi...
Source: European Journal of Pharmacology - August 20, 2023 Category: Drugs & Pharmacology Authors: Eman M Elbaz Alshaymaa Darwish Amany M Gad Amina A S Abdel Rahman Maheera H Safwat Source Type: research
Canagliflozin improves coronary microvascular vasodilation and increases absolute blood flow to the myocardium independent of angiogenesis
Sodium-glucose cotransporter-2 (SGLT-2) inhibitor, canagliflozin (CAN), improves myocardial perfusion to ischemic territory without accompanying changes in vascular density. We aimed to (1) characterize effects on angiogenic pathways, (2) utilize multiomics to identify gene expression and metabolite profiles relevant to regulation of myocardial blood flow, and (3) investigate drug effect on coronary microvascular reactivity. (Source: The Journal of Thoracic and Cardiovascular Surgery)
Source: The Journal of Thoracic and Cardiovascular Surgery - August 19, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Debolina Banerjee, Sharif A. Sabe, Hang Xing, Cynthia Xu, Mohamed Sabra, Dwight D. Harris, Mark Broadwin, M. Ruhul Abid, Anny Usheva, Jun Feng, Frank W. Sellke Source Type: research
What should be the eGFR decline thresholds on kidney endpoints?
We have read with great interest the article by Heerspink et al.1 regarding the effects of newer kidney protective agents on renal endpoints. The authors analyze whether differences were present in the estimated glomerular filtration rate (eGFR) decline thresholds used in the studies that evaluated renal outcomes in the Canagliflozin and Renal Events in Dia betes with Established Nephropathy Clinical Evaluation (CREDENCE), Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD), Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD), and the St...
Source: Kidney International - August 18, 2023 Category: Urology & Nephrology Authors: Jorge Rico-Fontalvo, Tomas Rodriguez-Yanez, Miriam Machado, Maria Jose Soler Tags: Letter to the Editor Source Type: research
